Abbott Laboratories (ABT) — The Transparent Read
45/100Neutral$92.71 · mixed
This is a stock fighting two timeframes. Short-to-medium momentum is genuinely constructive — above the 50-day, positive MACD, decent RSI — but it's bumping into resistance while the long-term structure remains broken below the 200-day with a death cross intact. My lean is cautiously neutral-to-slightly-constructive into resistance: the near-term setup and a modestly favorable macro base rate tilt the odds barely better than a coin flip. I'd want to see a decisive break above $95.21 before believing the medium-term momentum can overpower the damaged long-term trend.
ABT key levels
Show Your Work — every point in ABT's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Below 200-day MA Price is below its 200-day average — long-term trend is down. | technical | -8 |
| Above 50-day MA Trading above the 50-day average — medium-term momentum is positive. | technical | +5 |
| Death cross 50-day average is below the 200-day (death cross). | technical | -4 |
| RSI neutral RSI is 58 — neither overbought nor oversold. | technical | +0.82 |
| MACD positive MACD is above its signal line — momentum is building. | technical | +5 |
| Near resistance Pressing against resistance around $95.21. | technical | -4 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 53% of the time (median +1.7%). Historically favorable. | macro | +0.53 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, ABT was higher 90 days later 53% of the time (median move 1.7%). Confidence: high.
The read
ABT: Caught Between Short-Term Momentum and a Bruised Long-Term Trend
Bull case. The medium-term picture is improving. ABT is trading above its 50-day MA at 89.07, the MACD histogram is positive (+0.60) with momentum building above the signal line, and RSI at 58 sits in healthy neutral territory with room to run before overbought. The macro regime — rising inflation with a steady Fed — has historically favored ABT, higher 90 days later 53% of the time with a median gain of +1.7% across 38 analogous periods. Clear the $95.21 resistance and the path opens up.
Bear case. The long-term trend is the problem. Price sits well below the 200-day MA at 111.52, and the 50-day is below the 200-day — a textbook death cross signaling the larger trend is still down. ABT is also pressing right against resistance at $95.21, a level that has historically capped advances. A rejection here puts $85.60 support back in play. The composite score of 45.4 is squarely neutral for a reason.
What would change my mind. A clean daily close above $95.21 resistance flips this from neutral to bullish and would target a retest toward the 200-day at 111.52. Conversely, a break below $85.60 support confirms the bears, validates the death cross, and invalidates the constructive momentum read.
ABT — frequently asked
Is ABT a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 45/100 read for Abbott Laboratories (ABT), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is ABT's Tallyread score calculated?
The 45/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect ABT?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), ABT was higher 90 days later 53% of the time, with a median move of 1.7%. Confidence: high.
Want a fresh read on ABT with the live chart and macro tape?
Run a live ABT read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell ABT. Markets are uncertain; do your own research.